JP2021530236A5 - - Google Patents

Info

Publication number
JP2021530236A5
JP2021530236A5 JP2021502833A JP2021502833A JP2021530236A5 JP 2021530236 A5 JP2021530236 A5 JP 2021530236A5 JP 2021502833 A JP2021502833 A JP 2021502833A JP 2021502833 A JP2021502833 A JP 2021502833A JP 2021530236 A5 JP2021530236 A5 JP 2021530236A5
Authority
JP
Japan
Prior art keywords
heavy chain
monoantibody
sequence
disease
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021502833A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021530236A (ja
JP7439046B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/042633 external-priority patent/WO2020018922A1/en
Publication of JP2021530236A publication Critical patent/JP2021530236A/ja
Publication of JP2021530236A5 publication Critical patent/JP2021530236A5/ja
Priority to JP2024020312A priority Critical patent/JP7737488B2/ja
Application granted granted Critical
Publication of JP7439046B2 publication Critical patent/JP7439046B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021502833A 2018-07-20 2019-07-19 Cd19に結合する重鎖抗体 Active JP7439046B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024020312A JP7737488B2 (ja) 2018-07-20 2024-02-14 Cd19に結合する重鎖抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862701281P 2018-07-20 2018-07-20
US62/701,281 2018-07-20
PCT/US2019/042633 WO2020018922A1 (en) 2018-07-20 2019-07-19 Heavy chain antibodies binding to cd19

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024020312A Division JP7737488B2 (ja) 2018-07-20 2024-02-14 Cd19に結合する重鎖抗体

Publications (3)

Publication Number Publication Date
JP2021530236A JP2021530236A (ja) 2021-11-11
JP2021530236A5 true JP2021530236A5 (enExample) 2022-07-26
JP7439046B2 JP7439046B2 (ja) 2024-02-27

Family

ID=67515196

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021502833A Active JP7439046B2 (ja) 2018-07-20 2019-07-19 Cd19に結合する重鎖抗体
JP2024020312A Active JP7737488B2 (ja) 2018-07-20 2024-02-14 Cd19に結合する重鎖抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024020312A Active JP7737488B2 (ja) 2018-07-20 2024-02-14 Cd19に結合する重鎖抗体

Country Status (22)

Country Link
US (1) US12202898B2 (enExample)
EP (2) EP3823990B1 (enExample)
JP (2) JP7439046B2 (enExample)
KR (2) KR20260036383A (enExample)
CN (2) CN116769032A (enExample)
AU (2) AU2019305663B2 (enExample)
BR (1) BR112020024074A2 (enExample)
CA (1) CA3101069A1 (enExample)
DK (1) DK3823990T3 (enExample)
ES (1) ES3064933T3 (enExample)
FI (1) FI3823990T3 (enExample)
HR (1) HRP20260372T1 (enExample)
IL (2) IL326259A (enExample)
LT (1) LT3823990T (enExample)
MX (1) MX2021000708A (enExample)
PL (1) PL3823990T3 (enExample)
PT (1) PT3823990T (enExample)
RS (1) RS67881B1 (enExample)
SG (1) SG11202011597RA (enExample)
SI (1) SI3823990T1 (enExample)
SM (1) SMT202600121T1 (enExample)
WO (1) WO2020018922A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL299221A (en) 2016-06-21 2023-02-01 Teneobio Inc Cd3 binding antibodies
CN109862784A (zh) 2016-08-24 2019-06-07 特尼奥生物股份有限公司 产生经修饰的仅有重链的抗体的转基因非人动物
CR20220578A (es) 2016-09-14 2023-01-17 Teneobio Inc Anticuerpos de unión a cd3
EP3559035A1 (en) 2016-12-21 2019-10-30 TeneoBio, Inc. Anti-bcma heavy chain-only antibodies
CN110891971B (zh) 2017-06-20 2024-01-12 特尼奥生物股份有限公司 仅有重链的抗bcma抗体
JP7240335B2 (ja) 2017-06-20 2023-03-15 テネオワン, インコーポレイテッド 抗bcma重鎖のみ抗体
EA202091557A1 (ru) 2017-12-22 2020-11-18 Тенеобио, Инк. Антитела, содержащие только тяжелые цепи, которые связываются с cd22
LT3823990T (lt) 2018-07-20 2026-04-10 TeneoTwo, Inc. Antikūnai iš sunkiosios grandinės, besirišantys prie cd19
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
CA3133654A1 (en) 2019-04-05 2020-10-08 Teneobio, Inc. Heavy chain antibodies binding to psma
CN114206927B (zh) 2019-06-14 2025-03-21 特尼奥生物股份有限公司 与cd22和cd3结合的多特异性重链抗体
WO2021188599A1 (en) * 2020-03-16 2021-09-23 University Of Southern California Novel antigen binding domains and synthetic antigen receptors incorporating the same
UA130700C2 (uk) * 2020-04-29 2026-04-22 Тенеобіо, Інк. Поліспецифічні антитіла, що містять тільки важкі ланцюги, з модифікованими константними областями важкого ланцюга
KR20250007022A (ko) 2020-04-29 2025-01-13 테네오원, 인코포레이티드 변형된 중쇄 불변 영역을 갖는 다중특이적 중쇄 항체
CA3186065A1 (en) * 2020-07-16 2022-01-20 Xiaohu FAN Cd19 binding molecules and uses thereof
JP7846667B2 (ja) 2020-07-16 2026-04-15 レジェンド バイオテック アイルランド リミテッド Cd20結合分子及びその使用
AU2021345124A1 (en) 2020-09-16 2023-03-30 Amgen Inc. Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer
MX2023009882A (es) * 2021-02-26 2023-08-30 Teneobio Inc Anticuerpos anti-muc1-c y estructuras car-t.
PE20260568A1 (es) * 2021-04-06 2026-03-10 Teneobio Inc Anticuerpos anti-cd19 y estructuras car-t
WO2024243093A2 (en) * 2023-05-19 2024-11-28 The Regents Of The University Of California Multispecific antibodies targeting cd3 and cd22
EP4566619A1 (en) * 2023-12-08 2025-06-11 AvenCell Therapeutics Inc. Targeting modules against cd19 and cd20 for use in a method for stimulating a reversed chimeric antigen receptor-mediated immune response in a mammal
TW202608445A (zh) * 2024-04-19 2026-03-01 美商泰尼歐圖股份有限公司 用於治療b-細胞惡性腫瘤之阿卡替尼(acalabrutinib)及多特異性抗體之治療組合

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US6066721A (en) 1995-07-06 2000-05-23 Stanford University Method to produce novel polyketides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
AU6232899A (en) 1999-10-06 2001-05-10 Campina Melkunie B.V. Use of transforming growth factor beta and growth factors in the treatment and prevention of diseases of the intestinal mucosa
AU2002238052A1 (en) 2001-02-20 2002-09-04 Zymogenetics, Inc. Antibodies that bind both bcma and taci
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
MXPA05004677A (es) 2002-10-31 2005-11-17 Genentech Inc Metodos y composiciones para aumentar la produccion de anticuerpos.
WO2004065417A2 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
US20060008548A1 (en) 2003-11-19 2006-01-12 Invista North America S.A R.L. Spinneret plate for producing a bulked continuous filament having a three-sided exterior cross-section and a convex six-sided central void
EP1776383B1 (en) 2004-07-22 2014-08-20 Erasmus University Medical Center Rotterdam Binding molecules
PT1853718E (pt) * 2005-02-15 2015-11-12 Univ Duke Anticorpos anti-cd19 e usos em oncologia
CN101218351A (zh) * 2005-02-15 2008-07-09 杜克大学 抗cd19抗体及其在肿瘤学中的应用
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
KR101703299B1 (ko) 2007-06-01 2017-02-06 오픈 모노클로날 테크놀로지, 인코포레이티드 내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
AU2009272771B2 (en) * 2008-07-17 2012-09-20 Novartis Ag Compositions and methods of use for therapeutic antibodies
CN102421801B (zh) 2009-03-10 2016-03-16 比奥根Ma公司 抗-bcma抗体
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對bcma之e3以及cd3的結合分子
JP6636803B2 (ja) 2013-02-05 2020-01-29 エンクマフ エスアーエールエル Bcmaに対する抗体の選択のための方法
EA201790719A1 (ru) * 2014-09-26 2017-07-31 Макродженикс, Инк. Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения
CN105384825B (zh) * 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
US9914683B2 (en) 2016-05-26 2018-03-13 X Development Llc Fuel synthesis from an aqueous solution
IL299221A (en) 2016-06-21 2023-02-01 Teneobio Inc Cd3 binding antibodies
CN109862784A (zh) 2016-08-24 2019-06-07 特尼奥生物股份有限公司 产生经修饰的仅有重链的抗体的转基因非人动物
CR20220578A (es) 2016-09-14 2023-01-17 Teneobio Inc Anticuerpos de unión a cd3
EP3559035A1 (en) 2016-12-21 2019-10-30 TeneoBio, Inc. Anti-bcma heavy chain-only antibodies
CN110891971B (zh) 2017-06-20 2024-01-12 特尼奥生物股份有限公司 仅有重链的抗bcma抗体
JP7240335B2 (ja) 2017-06-20 2023-03-15 テネオワン, インコーポレイテッド 抗bcma重鎖のみ抗体
WO2019006072A1 (en) 2017-06-30 2019-01-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services CHIMERIC ANTIGENIC RECEPTORS TO ANTIGEN OF MATURATION OF LYMPHOCYTES B WITH HUMAN DOMAINS
EP3732199A1 (en) 2017-12-27 2020-11-04 TeneoBio, Inc. Cd3-delta/epsilon heterodimer specific antibodies
BR112020023975A2 (pt) 2018-05-24 2021-02-23 Ayala Pharmaceuticals Inc. composições que compreendem os compostos de bisfluoroalquil-1,4-benzodiazepinona e imunoterapêuticos e métodos de uso das mesmas
LT3823990T (lt) 2018-07-20 2026-04-10 TeneoTwo, Inc. Antikūnai iš sunkiosios grandinės, besirišantys prie cd19
CN114206927B (zh) 2019-06-14 2025-03-21 特尼奥生物股份有限公司 与cd22和cd3结合的多特异性重链抗体
KR20250007022A (ko) 2020-04-29 2025-01-13 테네오원, 인코포레이티드 변형된 중쇄 불변 영역을 갖는 다중특이적 중쇄 항체

Similar Documents

Publication Publication Date Title
JP2022505445A5 (enExample)
JP2022537931A5 (enExample)
JP2023526774A5 (enExample)
JP2024507540A5 (enExample)
US11987635B2 (en) Anti-4-1BB antibodies and methods of making and using thereof
AU2014228962B2 (en) Multimerization technologies
JP2022526595A5 (enExample)
RU2004121673A (ru) Человеческие полипептиды, вызывающие или опосредующие лизис клеток, включая клетки лимфоидных опухолей
JP2024062992A5 (enExample)
JP2023517753A5 (enExample)
JP2024508808A5 (enExample)
JP2024514107A5 (enExample)
RU99101121A (ru) Полипептиды, способные к образованию антигенсвязывающих структур со специфичностью к резус-d-антигенам, днк, кодирующая их, способы их получения и применение
WO2020172641A1 (en) Artificial immunosurveillance chimeric antigen receptor and cells expressing the same
JP2024516098A5 (enExample)
JP2026510999A (ja) Cd19/cd38多重特異性抗体
CN104105706A (zh) 用于治疗疾病的抗人sema4A抗体
JP2025530888A5 (enExample)
JP2022516301A (ja) Cd137アゴニスト性抗体とその使用
JP2024508360A (ja) 抗c4dキメラ抗原受容体調節性t細胞およびその使用
JPH05503687A (ja) 自己免疫疾患の治療
JP2024012258A (ja) Cd22に特異的なヒト化抗体およびそれを用いたキメラ抗原受容体
WO2023045370A1 (zh) 靶向tigit的单克隆抗体
CN116023496A (zh) 一种制备通用型car-t细胞的方法及其应用
CA2394295A1 (en) Antibodies against plasma cells